

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 2)\*

**Cyclerion Therapeutics, Inc.**

---

(Name of Issuer)

**Common Stock, no par value**

---

(Title of Class of Securities)

**23255M204**

---

(CUSIP Number)

**11/30/2024**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)
- 

SCHEDULE 13G

CUSIP No. 23255M204

Names of Reporting Persons

1

Slate Path Capital LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	0.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	0 %
12	Type of Reporting Person (See Instructions)
	IA, PN

## SCHEDULE 13G

**CUSIP No.** 23255M204

1	Names of Reporting Persons
	David Greenspan
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	UNITED STATES
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	0.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>

11 Percent of class represented by amount in row (9)  
0 %  
Type of Reporting Person (See Instructions)  
12 IN

## SCHEDULE 13G

### Item 1.

Name of issuer:

- (a) Cyclerion Therapeutics, Inc.  
Address of issuer's principal executive offices:  
(b) 245 First Street, 18th Floor, Cambridge, Massachusetts 02142.

### Item 2.

Name of person filing:

- (a) This statement is filed by: (i) Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership and the investment manager to certain funds (the "Slate Path Funds"), with respect to the shares of common stock, no par value ("Common Stock") of Cyclerion Therapeutics, Inc., a Massachusetts corporation (the "Issuer"), directly held by the Slate Path Funds; and (ii) David Greenspan ("Mr. Greenspan"), the managing partner of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Slate Path Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

Address or principal business office or, if none, residence:

- (b) The address of the business office of each of the Reporting Persons is 717 Fifth Avenue, 16th Floor, New York, NY 10022.  
Citizenship:

- (c) The Investment Manager is a Delaware limited partnership. Mr. Greenspan is a citizen of the United States.

Title of class of securities:

- (d) Common Stock, no par value  
CUSIP No.:  
(e) 23255M204

### Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);  
(b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);  
(c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);  
(d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);  
(e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);  
(f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);  
(g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);  
(h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);  
(i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);  
 A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in  
(j) accordance with § 240.13d-1(b)(1)(ii)(J),  
please specify the type of institution:  
(k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

### Item 4. Ownership

Amount beneficially owned:

- (a) 0

- (b) Percent of class:  
0 %
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:  
0
- (ii) Shared power to vote or to direct the vote:  
0
- (iii) Sole power to dispose or to direct the disposition of:  
0
- (iv) Shared power to dispose or to direct the disposition of:  
0

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Slate Path Capital LP

Signature: Jades GP, LLC, its General Partner, By: /s/ John Metzner

Name/Title: John Metzner, Chief Operating Officer

Date: 12/06/2024

David Greenspan

Signature: /s/ Jim Feeney

Name/Title: Jim Feeney, Attorney-In-Fact\*

Date: 12/06/2024

**Comments accompanying signature:** \* Pursuant to a Power of Attorney dated as of July 31, 2020 attached as Exhibit 2 to the Schedule 13G filed with the Securities and Exchange Commission on August 10, 2020.